The superior efficacy of this therapy arises from its novel dual-targeting mechanism, which employs a CD19 × CD3 bispecific antibody to engage endogenous T cells, thereby directing them to lyse leukemia cells (19, 20). This evidence concerns the gene CD19 and leukemia.